Sign In
Buy LUCD
$1.01
-0.0250 (-2.43%)
At Close: Jun 03, 2026
Lucid Diagnostics Launches New Corporate Website
08:31am, Thursday, 11'th Jul 2024
NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subs
Lucid Diagnostics (LUCD) Reports Positive ESOGUARD BE-1 Data
12:31pm, Thursday, 04'th Jul 2024
Lucid Diagnostic's (LUCD) ESOGUARD BE-1 study data shows high sensitivity and negative predictive value for the EsoGuard test, enhancing early detection of esophageal precancer in a screening populati
Prospective screening study demonstrates excellent EsoGuard sensitivity of 87.5% and negative predictive value (NPV) of 98.6% Previously announced positive data from a separate prospective VA screenin
4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing
08:05am, Wednesday, 12'th Jun 2024
Firefighter #CheckYourFoodTube Precancer Testing Event organized by Mass General Brigham physicians and Boston Firefighters Local 718 IAFF NEW YORK , June 12, 2024 /PRNewswire/ -- Lucid Diagnostics In
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024
06:00am, Monday, 20'th May 2024
No matter what anyone says, the very concept of penny stocks to buy must be treated with extreme skepticism. I'm not talking about having an aggressive mistrust toward such enterprises.
PAVmed Provides Business Update and First Quarter 2024 Financial Results
08:43pm, Monday, 13'th May 2024
Lucid strengthens balance sheet and secures a July 17, 2024 MolDX pre-submission meeting date Veris Health completes MOU with The Ohio State's James Cancer Hospital Conference call and webcast to be h
Lucid Diagnostics Inc. (LUCD) Q1 2024 Earnings Call Transcript
01:01pm, Monday, 13'th May 2024
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q1 2024 Earnings Conference Call May 13, 2024 8:30 AM ET Company Participants Matt Riley - Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Con
Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the
EsoGuard demonstrated unprecedented early precancer detection, including 89% sensitivity at detecting short segment early precancer, the primary target of esophageal precancer testing Publication furt
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month
08:47am, Monday, 29'th Apr 2024
NEW YORK , April 29, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned su
3 Penny Stocks That Could Make a Big Comeback by the End of Q2
06:00am, Friday, 19'th Apr 2024
Let's just get something straight off the bat – penny stocks to rebound are risky. They're incredibly treacherous in terms of both short-term downside and longer-term damage to your portfolio.
Lucid Diagnostics Inc. (LUCD) Q4 2023 Earnings Call Transcript
04:27pm, Tuesday, 26'th Mar 2024
Lucid Diagnostics Inc. (LUCD) Q4 2023 Earnings Call Transcript
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results
05:30pm, Monday, 25'th Mar 2024
Quarterly EsoGuard® revenue increased 33 percent sequentially Expanding EsoGuard clinical validity and clinical utility data poised to drive medical policy coverage, including line of sight to Medica
Prospective VA screening study demonstrates excellent EsoGuard sensitivity of 92.9% and negative predictive value of 98.6% compared to upper gastrointestinal endoscopy Authors conclude that EsoGuard i
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
08:30am, Wednesday, 20'th Mar 2024
Lucid and collaborators will present data on three studies on EsoGuard® esophageal precancer testing and one on a new genetic classifier of esophageal neoplasia NEW YORK , March 20, 2024 /PRNewswire/
